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agonism. This novel immunotherapeutic approach has the 
potential to active antitumor immune effectors by a com-
plementary mechanism: simultaneously “removing the 
brakes” via blocking inhibitory signaling and “stepping on 
the accelerator” via co-stimulation. While important con-
siderations should be given to 4-1BB-mediated toxicities, 
the current understanding of 4-1BB biology suggests it 
may play a key role in advancing the capabilities of cancer 
combination therapy.
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Abbreviations
ADCC  Antibody-dependent cell-mediated cytotoxicity
ALT  Alanine aminotransferase
AST  Aspartate aminotransferase
BMS  Bristol-Myers Squibb
DLT  Dose-limiting toxicity
NCT  National Clinical Trial
NKT  Natural killer T cell
PF  Pfizer
TME  Tumor microenvironment
Treg  Regulatory T cell
Introduction
4-1BB (CD137/TNFRSF9) was discovered in 1989 dur-
ing screens for novel receptors on murine T-cell lines [1]. 
Using stimulation with concanavalin A (Con A), Kwon and 
Weissman identified 4-1BB as an inducible gene on T cells 
and successfully cloned the 4-1BB cDNA. In the last two 
decades, our understanding of the biology and function of 
Abstract The success of checkpoint inhibitors has vali-
dated immunomodulatory agents as a valuable class of 
anticancer therapeutics. A promising co-stimulatory 
immunologic target is 4-1BB, or CD137, a member of the 
tumor necrosis factor receptor superfamily. Ligation of 
4-1BB induces an activating signal in CD8+ T cells and 
natural killer cells, resulting in increased pro-inflamma-
tory cytokine secretion, cytolytic function, and antibody-
dependent cell-mediated cytotoxicity. Targeting 4-1BB 
with agonistic monoclonal antibody (mAb) therapy dem-
onstrated potent antitumor effects in murine tumor mod-
els. While anti-4-1BB mAbs have entered clinical trials, 
optimal efficacy of 4-1BB-targeted agents will inevitably 
come from combination therapeutic strategies. Checkpoint 
blockade is a compelling combination partner for 4-1BB 
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4-1BB has expanded tremendously. 4-1BB is now accepted 
as an activation-induced, co-stimulatory receptor that gov-
erns the function of diverse immune cell subsets. With the 
advent of cancer immunotherapy, targeting 4-1BB emerged 
as a promising therapeutic strategy. Analogously to check-
point inhibitors “removing the brakes” on tumor-targeting 
effectors, 4-1BB co-stimulation may result in “pressing the 
accelerator,” or increasing immune effector cytotoxicity. 
Recently, two different monoclonal antibodies (mAb) tar-
geting 4-1BB have entered clinical testing. In this review, 
we present the current understanding of 4-1BB expression 
and signaling and discuss the potential of 4-1BB mAb ther-
apy to eradicate tumor and synergize with other therapeutic 
modalities.
4‑1BB expression and signaling
The expression of 4-1BB has been reported on diverse 
immune cell populations. On T cells, natural killer (NK) 
cells, regulatory T cells (Treg), and NK T cells (NKT), 
4-1BB expression is activation dependent [2]. Some of the 
canonic immunostimulatory agents known to induce 4-1BB 
upregulation on T cells include: Con A, plate-bound anti-
CD3, CD28, phorbol myristoyl acetate (PMA), ionomycin, 
phytohemagglutinin, interleukin (IL)-2, or IL-4 [3, 4]. On 
NK cells, 4-1BB is upregulated following ligation of the 
FcRγIII Fc receptor (CD16) by the Fc portion of mAb. 
In addition to activated immune effectors, 4-1BB is also 
expressed on innate immune cell populations, including 
neutrophils, granulocytes, monocytes, mast cells, eosino-
phils, and dendritic cells (DC) [5]. Expression of 4-1BB 
has recently been shown on subtypes of lymphomas and 
leukemias, but its role in malignant transformation remains 
unclear [6, 7].
Once expressed, 4-1BB binds to a high-affinity 4-1BB 
ligand (4-1BBL or CD137L). 4-1BBL is predominantly 
expressed by activated antigen-presenting cells (APCs), 
including B cells, DCs, and macrophages [8]. Upon liga-
tion and crosslinking, 4-1BB associates with the tumor 
necrosis factor (TNF)-associated factors 1 and 2 (TRAF1 
and TRAF2) and activates the master immunoregulatory 
transcription factor NF-κB. In T cells, 4-1BB signaling 
upregulates the antiapoptotic B-cell lymphoma-extra large 
(Bcl-xl) and B-cell lymphoma 2 (Bcl-2) pathways and 
induces proliferation and production of pro-inflammatory 
cytokines interferon gamma (IFN-γ) and IL-2 [9, 10]. Fur-
thermore, 4-1BB stimulation increases signaling through 
the T-cell receptor (TCR) and amplifies the cytotoxicity of 
CD8+ T cells [11]. Similarly, in NK cells, CD137 stimu-
lation enhances proliferation, IFN-γ production, and cytol-
ytic action [12]. In DCs, CD137 ligation accelerates matu-
ration through upregulation of B7 co-stimulatory molecules 
(CD80 and CD86) and increases survival and production of 
IL-6 and IL-12 [13].
4‑1BB in cancer immunotherapy
The initial evidence that anti-4-1BB agonistic mAbs may 
have strong antitumor effects emerged from studies on the 
highly tumorigenic P815 mastocytoma and poorly immu-
nogenic Ag104A sarcoma [14]. Administration of anti-
4-1BB mAb eradicated established tumors in both mod-
els and generated increased numbers of tumor-specific 
cytotoxic T cells. Importantly, anti-4-1BB mAb therapy 
appeared to trigger an immunologic memory response: 
Mice that had been cured of P815 tumor were challenged 
3 months later with P815 cells and, after a period of tran-
sient growth, all tumors regressed. The antitumor capac-
ity of 4-1BB-targeted mAb has since been replicated in a 
variety of tumor models, including lymphoma, hepatocel-
lular carcinoma, and colon cancer [15–17]. The mechanism 
of action underpinning 4-1BB-mediated tumor regression 
consists of multiple, complimentary antitumor immune 
pathways. Primarily, 4-1BB agonism induces a potent, 
cytotoxic T-cell population that can infiltrate and lyse 
tumors [18]. In addition to direct tumor lysis, 4-1BB stimu-
lation promotes the secretion of type 1 cytokines, creating 
an inflammatory, immunogenic cytokine milieu within the 
tumor microenvironment (TME) [19]. Finally, 4-1BB liga-
tion increases the secretion of perforin and granzyme and 
activation of the Fas ligand (FasL) effector system by both 
CD8+ T cells and NK cells [20].
4‑1BB stimulation enhanced ADCC
The role of antibody-dependent cell-mediated cytotoxicity 
(ADCC) is increasingly appreciated as an important com-
ponent of antibody-mediated antitumor effects [21, 22]. 
In ADCC, FcγRIII (CD16) ligation by the Fc domain of 
immunoglobulins transmits activating signals within NK 
cells. In the cancer setting, tumor-targeted mAb is recog-
nized by NK cell FcγRIII, triggering release of perforin 
and granzyme [23]. These direct cytotoxic effects are com-
plemented by a release of interferon gamma (IFN-γ) which 
can recruit adaptive immune cells and promote antigen 
presentation by APCs [24]. Human NK cells upregulate 
4-1BB after FcRIII ligation, and subsequent stimulation 
with anti-4-1BB mAb enhances ADCC. Enhanced ADCC-
mediated tumor clearance makes anti-4-1BB antibod-
ies an ideal candidate for therapeutic combinations with 
FDA-approved mAbs. We have previously demonstrated 
that antibodies targeting 4-1BB synergize with rituximab 
(anti-CD20) and trastuzumab (anti-HER2) to clear tumors 
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in murine xenograft models of lymphoma and breast can-
cer [25, 26]. The synergistic therapeutic effect was depend-
ent on FcγRIII expression and observed in mice compe-
tent in NK cells and macrophages, but lacking an adaptive 
immune system. Recently, we combined cetuximab (anti-
EGFR) and anti-4-1BB antibody therapy to obtain com-
plete tumor resolution and prolonged survival in models 
of colorectal cancer and head and neck cancer [27]. Based 
on the preclinical successes of antibodies targeting 4-1BB, 
two agonistic anti-4-1BB mAb entered clinical testing.
4‑1BB clinical trials
The two anti-4-1BB mAbs currently in the clinic are ure-
lumab (Bristol-Myers Squibb), a fully humanized IgG4 
mAb, and PF-05082566 (Pfizer), a fully human IgG2 mAb 
(Table 1). Urelumab is now being tested in multiple combi-
natorial regimens: cetuximab in head and neck or colorec-
tal cancer, rituximab in relapsed or refractory B-cell NHL, 
and elotuzumab (anti-SLAMF7) in multiple myeloma. 
PF-05082566 is currently in three clinical trials, and results 
of the phase I monotherapy study were recently reported 
[28]. Out of 27 treated patients, the best clinical response 
was disease stabilization, occurring in 22 % (6/27) of 
patients. Importantly, PF-05082566 did not induce any 
dose-limiting toxicities (DLTs), and all study discontinu-
ations were from disease progression, not adverse events. 
Ongoing clinical studies test PF-05082566 in combination 
with rituximab and mogamulizumab (anti-CCR4).
As anti-4-1BB targeted agents advance in clinical tri-
als, monitoring potential toxicities is a chief responsi-
bility. Liver inflammation was observed during 4-1BB 
monotherapy, characterized by elevated levels of aspar-
tate aminotransferase (AST) and alanine aminotransferase 
(ALT). Grade 2+ neutropenia, leukopenia, and thrombocy-
topenia were also observed [29]. Potentially fatal hepatitis 
was later observed in a Bristol-Myers Squibb (BMS) phase 
II anti-4-1BB study for previously treated stage III/IV 
melanoma, National Clinical Trial (NCT) 00612664. This 
study and several others (NCT00803374, NCT00309023, 
NCT00461110, NCT00351325) were terminated due to 
these adverse events. Despite this clinical hurdle, further 
studies have proven that hepatic toxicity due to 4-1BB ago-
nist antibodies can be largely mitigated by lowering the 
dose of anti-4-1BB mAb administered.
4‑1BB and checkpoint inhibitors
Checkpoint inhibitors are a novel and promising class of 
immunotherapeutic antibodies and have evoked impres-
sive clinical responses to melanoma, non-small-cell lung 
cancer, and renal cancer. Immune checkpoints are inhibi-
tory pathways that downregulate activated T cells follow-
ing antigen presentation and co-stimulatory signaling by 
APCs. Currently, two checkpoint receptors have been tar-
geted by FDA-approved mAbs: CTLA-4, targeted by ipili-
mumab, and programmed death (PD)-1. The recent approv-
als of PD-1 blocking mAb pembrolizumab and nivolumab 
Table 1  List of anti-4-1BB mAb clinical trials
a NCT National Clinical Trial
b BMS Bristol-Myers Squibb
c PF Pfizer
NCT numbera Phase Condition Combination Start year Status (2014/12)
Urelumab (BMS-663513)b: fully human type IgG4, Bristol-Myers Squibb
NCT00309023 I/II Metastatic or locally advanced solid tumors – 2005 Terminated
NCT00351325 I Advanced solid malignancies Chemotherapy 2007 Terminated
NCT00461110 I Non-small cell lung cancer Chemoradiation 2008 Terminated
NCT00612664 II Melanoma – 2008 Completed
NCT00803374 I Advanced malignant melanoma Ipilimumab (anti-CTLA-4 mAb) 2010 Withdrawn
NCT01471210 I Advanced and/or metastatic solid tumors
Relapsed/refractory B-cell non-Hodgkin’s lymphoma
– 2012 Recruiting
NCT01775631 Ib Relapsed/refractory B-cell non-Hodgkin’s lymphoma Rituximab (anti-CD20 mAb) 2013 Recruiting
NCT02110082 Ib Colorectal cancer, head and neck cancer Cetuximab (anti-EGFR mAb) 2014 Recruiting
NCT02252263 I Multiple myeloma Elotuzumab (anti-CS1 mAb) 2014 Recruiting
NCT02253992 I/II Advanced solid tumors, advanced B-cell NHL Nivolumab (anti-PD-1 mAb) 2014 Recruiting
PF-05082566c: fully human type IgG2, Pfizer
NCT01307267 I CD20 positive non-Hodgkin’s lymphoma Rituximab (anti-CD20 mAb) 2011 Recruiting
NCT02179918 Ib Advanced solid tumors MK-3475 (anti-PD-1 mAb) 2014 Recruiting
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validate the effectiveness of checkpoint blockade strategy in 
the setting of clinical oncology. Conceptually, the addition 
of 4-1BB agonists to a therapeutic backbone of checkpoint 
blockade is highly appealing. This combination targets two 
distinct elements in the process of immune effector activa-
tion: overcoming inhibition and co-stimulation. Checkpoint 
inhibitors can block the inhibitory signals that pervade the 
immunosuppressive TME, while 4-1BB stimulation can 
augment effector cells’ baseline cytotoxic capacity. If both 
molecules are simultaneously targeted, selective activation 
of tumor-targeting T and NK cells may occur, releasing a 
robust antitumor immune response. To date, there is strong 
clinical preclinical evidence to support this combination.
The combination of anti-CTLA-4 antibodies and anti-
4-1BB has demonstrated preclinical success in multiple 
tumor histologies. In the B16 melanoma model, the com-
bination showed a synergistic curative effect and induced 
antitumor TME remodeling; after therapy, the number of 
CD8+ T cells infiltrating the tumor increased, while the 
numbers of Tregs and myeloid-derived suppressor cells 
(MDSCs) decreased [30]. In the RM-1 prostate cancer 
model, a 4-1BBL-expressing tumor cell vaccine combined 
with CTLA-4 blockade caused tumor rejection in four 
out of five mice implanted with RM-1 tumors [31]. In the 
MC38 colon adenocarcinoma model, the combination of 
anti-4-1BB mAb and anti-CTLA-4 antibody led to the era-
diation of large, established tumors (>7 mm in diameter) 
in seven out of eight mice and induced long-lasting immu-
nity to rechallenge with MC38 cells [32]. More importantly 
than the observed synergistic therapeutic activity, Kocak 
et al. [32] demonstrated that combining anti-4-1BB with 
anti-CTLA-4 has the potential to ameliorate the toxicities 
observed with monotherapeutic use of anti-4-1BB mAb. 
Anti-CTLA-4 therapy reduced the 4-1BB-induced influx 
of T cell infiltrates into the liver and prevented the hepatic 
toxicity that has limited 4-1BB application in the clinic.
The PD-1 blocking mAbs nivolumab and pembroli-
zumab have demonstrated comparable therapeutic activity 
to ipilimumab while also having a milder toxicity profile. 
These observations suggest that PD-1 blockade may be 
superior to anti-CTLA-4 antibodies for combination with 
4-1BB agonists. In one of the first preclinical models of 
this therapeutic strategy, Xiao et al. [33] combined soluble 
PD-1 with naked plasmid p4-1BBL-transfected H22 tumor 
cells in an ectopic hepatocarcinoma model. This combina-
tion demonstrated robust therapeutic synergy, increasing 
the number of infiltrating T cells and eradicating 60 % of 
established tumors. Recent testing of anti-4-1BB with PD-1 
blockade further supports the argument for combinatorial 
synergy. In the CT26 colon adenocarcinoma model, com-
bining 4-1BB agonism and anti-PD-1 mAb resulted in 
complete tumor rejection in all mice injected with CT26 
cells [34]. In the poorly immunogenic B16-F10 melanoma 
model, combination therapy again resulted in complete 
tumor regression and an increased ratio of CD8+ T cells 
to Tregs [35]. However, Chen et al. [35] also demonstrated 
that the combination of anti-4-1BB and anti-PD-1 may 
exacerbate toxicities observed with anti-4-1BB monother-
apy. At the higher dose levels of anti-4-1BB mAb (1 and 
5 mg/kg), AST and ALT levels were elevated over twofold 
what was reported with anti-4-1BB monotherapy and the 
combination intensified anti-4-1BB-induced neutropenia, 
lymphopenia, and thrombocytopenia. These results suggest 
that PD-1 blockade may be a potent therapeutic partner for 
anti-4-1BB, but clinicians must progress cautiously with 
early-phase trials until an appropriate dosage is established.
Another approach to inhibiting the PD-1-mediated sup-
pressive signaling is to block the ligand of PD-1 ligand 
(PD-L1). This approach has exhibited exciting early data, 
and currently, four clinical anti-PD-L1 mAbs are in test-
ing: atezolizumab and MEDI4736 (both Fc null variants 
of human IgG1), MSB001078C (IgG1), and BMS-936559 
(IgG4). In the ID-8 ovarian adenocarcinoma model, the 
combination of anti-PD-L1 and anti-4-1BB antibodies 
increased overall survival and enhanced T-cell effector 
function [36]. As anti-PD-L1 mAbs advance in clinical 
trials, combination therapy with anti-4-1BB mAbs will 
undoubtedly receive increased consideration. Currently, 
4-1BB and anti-PD-1 checkpoint inhibitors are the focus of 
ongoing clinical trials. A phase I/II trial of urelumab with 
nivolumab in both solid tumors and B-cell non-Hodgkin’s 
lymphoma is recruiting participants (NCT02253992), while 
PF-05082566 is being tested in a phase Ib trial with pem-
brolizumab in patients with solid tumors (NCT02179918).
4‑1BB and cancer vaccines
Recently, there has been a renewed focus on therapeu-
tic cancer vaccines. The allure of vaccine strategies is the 
potential to “teach” individual patients’ immune systems to 
recognize, target, and eradicate tumor cells in an approach 
that employs both adaptive and innate immunity. Vac-
cines aim to provoke a tumor-specific immune response 
by increasing TAA presentation by APCs, thus generating 
tumor antigen-specific cytotoxic T lymphocytes. Unlike 
chemotherapy, surgery, radiotherapy, or antibody ther-
apy, an effective vaccine-induced immune response could 
establish a state of immunologic memory that persists 
after tumor clearance and indefinitely suppresses tumor 
regrowth. Mechanistically, the combination of vaccine 
strategies and anti-4-1BB targeted agents is compelling 
because it targets synergistic and non-overlapping compo-
nents of the antitumor immune response; vaccines gener-
ate an immune response and anti-4-1BB further activates 
tumor-targeted effector populations.
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Ongoing efforts to combine cancer vaccines and anti-
4-1BB agents have demonstrated early progress. In the 
HPV E6/E7-driven TC-1 murine cervical cancer model, 
vaccination with HPV E6/E7 peptides in conjunction with 
systemic 4-1BB agonistic antibody induced durable tumor 
regression in five out of eight mice. Surviving mice that 
were rechallenged with additional TC-1 cells demonstrated 
strong CD8+ T cell memory responses, remaining tumor 
free. Anti-4-1BB antibodies proved to be a superior combi-
nation partner for vaccine therapy, demonstrating superior 
results relative to CTLA-4 and PD-1 checkpoint inhibitors 
as well as other TNF family receptors [37]. In a MCA205 
murine fibrosarcoma model, a tumor lysate-pulsed den-
dritic cell vaccine (TP-DC) combined with α4-1BB signifi-
cantly reduced lung metastases. The combined therapy also 
led to regression of lung tumors in a B16-BL6 melanoma 
model [38].
Conclusion
Significant progress has been made in recent years in elu-
cidating the expression, function, and therapeutic potential 
of 4-1BB. The ongoing clinical trials dedicated to 4-1BB 
agonists portend the viability of 4-1BB as an important 
immunotherapeutic target. The maximal clinical efficacy 
of 4-1BB will emerge in combination treatment strategies, 
and checkpoint inhibitors are a compelling class of partner 
candidates. However, the broad range of 4-1BB expression 
makes off-target immune pathology an acute risk. Further 
research is needed to optimize approaches to harnessing 
4-1BB-mediated antitumor effects, while minimizing auto-
inflammatory complications. If this goal can be achieved, 
4-1BB agonists may provide a critical component of future 
anticancer combination therapies.
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